NEW Zealand's pharmaceutical regulatory body PHARMAC (Pharmaceutical Management Agency) has approved a multiproduct agreement with Merck Sharpe & Dohme (MSD).
The new arrangement will see once-daily presentation of raltegravir for the treatment of HIV, once it is registered with Medsafe, as well as changes to the contractual arrangements for the currently funded presentations of raltegravir and posaconazole.
The above article was sent to subscribers in Pharmacy Daily's issue from 14 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 19
